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Aim To evaluate whether tumor infiltrating lymphocytes 
(TIL) in biopsy specimens are associated with the clinical 
outcome of non-muscle invasive bladder cancer.
Methods We retrieved tumor specimens from 115 pa-
tients with solitary papillary non-muscle invasive bladder 
cancer treated between 1996 and 2006 and constructed 
tissue microarrays. Patients were divided in two groups: 
those with recurrent disease (N = 69) and those without re-
current disease (N = 46) during the follow up of minimum 
5 years. All patients were treated with initial transurethral 
resection and none received adjuvant therapy. Immunhis-
tochemical staining was performed with anti-CD3, CD4, 
CD8, and Granzyme B (GrB). The CD4+:CD8+ and GrB+:CD8 
ratios were determined.
Results Tumor infiltrating lymphocytes were predomi-
nantly observed within cancer stroma, and only rare in-
dividual cells were observed intraepithelially. The group 
without recurrent disease had lower levels of CD3+ and 
CD8+ lymphocytes than the group with recurrent disease 
(P = 0.0001, P = 0.0002, respectively). The CD4+:GrB+ and 
GrB+:CD8+ ratios were significantly higher in patients with-
out recurrent disease (P = 0.0002, P = 0.039, respectively).
Conclusion This study revealed a possible connection be-
tween TIL number and bladder cancer recurrence. TIL sub-
set ratio showed different patterns in recurrent and non-
recurrent tumors, which is why it could become a useful 
a prognostic clinical index if our findings are confirmed in 
randomized trials. Received: May 2, 2012
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Bladder cancer is the most common malignancy of the uri-
nary tract (1), with non-muscle invasive bladder carcinoma 
being its most frequent type (75%-85% of patients) (NMIBC, 
stages pTa, pT1, pTis). These tumors form a very heteroge-
neous group, with various clinical outcomes. The main clini-
cal feature of bladder cancer is the high recurrence rate. In 
fact, 70% of the patients treated by transurethral resection 
(TUR) experience a relapse of the underlying disease, while 
in 15%-25% the disease over time turns into muscle-inva-
sive cancer (2). Given that multiple different therapeutic 
approaches are available, assessing the risk of tumor recur-
rence and progression is the key task in developing individ-
ualized and accurate adjuvant treatment (3,4).
Urinary bladder carcinoma is the only malignant neoplasm 
whose treatment often includes immunotherapy. The re-
currence rate and risk of progression to muscle-invasive 
disease in patients with non-muscle-invasive urothelial 
carcinomas has been reduced by intravesical instillation 
of Bacille Calmette-Guerin (BCG) (5,6). Although some 
variables that predict the recurrence have been used to 
identify patients who require adjuvant therapy after TUR, 
additional reliable markers for disease progression and re-
currence are needed (7,8). BCG induces a massive influx 
of cytokines and inflammatory cells into the bladder wall 
and lumen, and its antitumor activity may be generally at-
tributed to potent activation of cellular immunity (9,10). 
Tumor-infiltrating immune cells are thought to play an im-
portant role in preventing disease progression and thera-
peutic efficacy in other cancers (11-15). Thus, the aim of 
the present study was to determine the association of tu-
mor infiltrating lymphocytes and solitary papillary NMIBC 
in biopsy specimens obtained from patients grouped 
according to development of the recurrent disease. We 
hypothesize that such investigation could be helpful in 




During 2010 and 2011, we collected data on all 115 pa-
tients with solitary papillary NMIBC who underwent initial 
transurethral resection, which is a standard treatment regi-
men at the Department of Urology, Rijeka University Hos-
pital Center in Rijeka, between 1996 and 2006. The data 
were gathered from hospital charts and medical histories. 
We included only the patients operated on till 2006 to en-
sure the follow-up of a minimum 5 years.
None of the patients received adjuvant chemotherapy, im-
munotherapy, or any other medical intervention after the 
initial TUR. All patients with multiple tumors and patients 
with a solid or flat aspect were excluded from this study. 
The study was approved by the University of Rijeka Ethics 
Committee and all patients signed informed consent.
All sections were reviewed to confirm the original diagno-
sis and were then staged according to the 2002 American 
Joint Committee on Cancer (16) and graded according to 
the 2004 World Health Organization classification system 
(17) by an expert urologic pathologist (GĐ). All tumors 
were classified as papillary urothelial neoplasm of low ma-
lignant potential or low-grade papillary urothelial carci-
noma. Patients were divided in two groups: patients who 
developed recurrent disease (study group, N = 69) and pa-
tients who did not develop recurrent disease during the 
follow-up of a minimum 5 years (control group, N = 46). 
The follow-up of patients was scheduled at control cystos-
copy for every 3 months during the first two years after 
TUR, and after that biannually. Recurrence was defined as 
a written description of the recurrent tumor at any control 
cystoscopy 6 months after the operation, localized away 
from the primary tumor bed and the area of the initial re-
section to exclude all possible residual tumor masses.
tissue microarray construction (tma)
On hematoxylin and eosin stained tumor sections, we 
marked the areas with the most pronounced inflamma-
tory infiltration. On each slide, an expert uropathologist 
chose three “hot-spots,” which were then analyzed for TIL 
count. These “hot-spots” were defined as the areas of the 
most prominent peritumoral mononuclear infiltration (18). 
Paraffin blocks were available for all 115 cases, and tissue 
microarrays (TMA) were constructed by using a manual 
tissue arrayer (Alphelys, Plaisir, France). Three tissue cores, 
each 1 mm in diameter, were placed into a recipient paraf-
fin block. Normal liver tissue was used for orientation. The 
cores were spaced at intervals of 0.5 mm along the x- and 
y-axis. One section from each TMA block was stained with 
hematoxylin and eosin to confirm the presence of tumor 
tissue. Serial sections were cut from TMA blocks for immu-
nohistochemical staining. Three to four micrometers-thick 
sections were placed on adhesive glass slides (Capillary 
Gap Microscope Slides, 75 μm, Code S2024, DakoCytoma-
tion, Glostrup, Denmark), left to dry in the oven at 55°C 
overnight, and were deparaffinized and rehydrated. 
TMAs were created and interpreted by two expert uro-
pathologists and one pathologist. The same three 
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pathologists were involved in reading of the results and 
reached a consensus on all the results.
immunohistochemistry and evaluation of staining by 
computerized image analysis
Tumor samples were subjected to immunohistological 
analysis in a Dako Autostainer Plus (DakoCytomation Col-
orado Inc, Fort Collins, CO, USA) according to the manu-
facturer’s protocol using Envision peroxidase procedure 
(ChemMate TM Envision HRP detection kit K5007, DakoCy-
tomation) and different antibodies for immunohistochem-
ical staining, including epitope retrieval, dilution, and incu-
bation (Table 1).
All antibody-stained slides were scanned and analyzed with 
Alphelys Spot Browser 2 integrated system, using software-
controlled (Alphelys Spot Browser 2.4.4.) stage positioning 
Nikon Eclipse 50i microscope-mounted 1360 × 1024 reso-
lution Microvision CFW-1310C digital camera. The slides 
were scanned at 20 × magnification to identify the section 
area of the slide and then at 200 × magnification to create 
images for quantification and scoring positive cells. Posi-
tive cells were counted in the tumor stroma, lymphoid ag-
gregates, and intraepithelially, and presented as absolute 
numbers and as a proportion of positive cells in the total 
inflammatory infiltrate. In statistical analysis, the mean val-
ue of immunohistochemical staining of all three tissue mi-
croarrays was used.
t lymphocyte subpopulation analysis
In order to determine the exact level of immunobiologi-
cal interactions in the bladder of these patients, we also 
used subset ratio analysis because it had been previously 
shown that this ratio more accurately represented the im-
munobiological status of the patient than the number of 
infiltrated cells (19-21).
statistical analysis
Statistical analysis was performed using SPSS 20 software 
(SPSS Inc., Chicago, IL, USA). The distribution of data was 
tested for normality using D’Agostino-Pearson test. Inde-
pendent t test and Mann-Whitney U test were used to as-
sess whether continuous variables differed significantly 
between categories, depending on data distribution.
REsults
The median patients’ age at diagnosis was 73 years (range 
41-86), with a male-to-female ratio of 3.3:1, and a median 
follow-up period of 73.5 months (range 6-155). This range 
is so wide because all patients had a lifelong follow-up, but 
for the purposes of the study the follow-up duration in pa-
tients with recurrent disease was determined to be until 
the recurrence and in patients without recurrent disease a 
minimum of 5 years. The recurrence was observed in 69 pa-
tients (60%). Clinical and pathological characteristics were 
taBlE 1. antibodies used for immunohistochemical staining
antigen Catalog number species Clone source Epitope retrieval dilution incubation Positive control
CD 3 M 7254 Mouse mAb F7.2.38 DakoCytomation Citrate buffer pH 6.0,  
microwave oven 25 min
1:100 30 min/RT* appendix
CD 4 NCL-L-CD4-368 Mouse mAb 4B12 Novocastra EDTA buffer pH 8, 
microwave oven 25 min
1:75 60 min/RT tonsil
CD 8 M 7103 Mouse mAb C8/144B DakoCytomation Tris/EDTA buffer pH 9.0 and 
water bath at 98°C for 15 min
1:100 30 min/RT tonsil
GrB M 7235 Mouse mAb GrB-7 DakoCytomation Tris/EDTA buffer pH 9.0,  
microwave oven 25 min
1:35 60 min/RT tonsil
*Rt – room temperature; GrB – Granzyme B.
taBlE 2. Clinicopathologic characteristics of patients with 
non-muscle invasive bladder carcinoma*
No. (%) of patients
with recurrent 
disease (n = 69)
without recurrent 
disease (n = 46)
sex:
male 52 (75) 36 (78)
female 17 (25) 10 (22)
age in years (median, range) 74.4 (41-87) 71.8 (54-78)
tumor size:
>3 cm 40 (58) 19 (41)
≤3 cm 29 (42) 27 (59)
Pathology:
PUNLMP 26 (38) 28 (61)
LGPUC 43 (62) 18 (39)
median follow-up (months) 13 75
*abbreviations: PuNlmP – papillary urothelial neoplasm of low malig-
nant potential; lGPuC – low-grade papillary urothelial carcinoma.
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equally distributed, ie, 51% of patients had tumors larger 
than 3 cm and 53% of patients had pT1 stage (Table 2).
Tumor infiltrating lymphocytes (TIL) CD3+, CD4+, CD8+, 
and GrB+ were predominantly observed within the can-
cer stroma, especially in the papillary-axis, underlying stro-
ma, and lymphoid aggregates, and only rarely as individual 
cells within the epithelial part of the tumor (Figure 1).
We analyzed the number of CD3+, CD4+, CD8+, and 
GrB+ cells in each patient. The group without recurrence 
had significantly fewer infiltrating CD3+ and CD8+ T cells 
(P = 0.0001, P = 0.0002, respectively), but no significant dif-
ferences in the number of CD4+ and GrB+ cells were ob-
served between the groups (P = 0.561 [95% confidence 
interval -8-4], P = 0.654 [95% confidence interval -1-1], re-
spectively) (Table 3).
FiGuRE 1. immunohistochemical staining with anti-Cd8 (A) and Granzyme B (B) in representative tumor samples of non-muscle 
invasive bladder cancer (original magnification 100 × ). (A) abundant tumor infiltrating Cd8 lymphocytes predominantly within the 
cancer stroma accompanied by rare individual cells within the epithelial part (indicated by asterisk) of the tumor. (B) scatter single 
Granzyme B positive cells (arrows) in the tumor stroma and representative high-power (400 × magnification) image (upper panel).
taBlE 3. the number of tumor-infiltrating lymphocytes in the groups of patients with and without recurrent disease
Recurrent disease
marker expression yes (n = 69) no (n = 46) P 95% confidence interval
CD 3 (mean ± standard deviation, %) 46 ± 17 30 ± 14 0.0001* 10.13-22.21
CD 4 (median, range, %) 32 (2-67) 34.5 (8-61) 0.561† -8-4
CD 8 (median, range, %) 16 (1-32) 11.5 (1-32) 0.0002†  2-8
GrB (median, range, %)  3 (0-17)  3 (0-13) 0.654† -1-1
*independent t test.
†mann- Whitney u test.
taBlE 4. the ratio between Cd4+:Cd8+ and Granzyme B+:Cd8+ t lymphocytes in the groups of patients with and without recurrent 
disease (N = 115)
Recurrent disease
Ratio yes (n = 69) no (n = 46) P* 95% confidence interval
Cd4:Cd8
median (range) 1.86 (0.06-39) 3.39 (0.45-14) 0.0002 -2.267 to -0.775
mean ± standard deviation 2.69 ± 4.9 3.97 ± 2.87
GrB:Cd8
median (range) 0.17 (0-1.17) 0.23 (0.04-3) 0.039 -0.1428 to -0.0037
mean ± standard deviation 0.26 ± 0.28 0.40 ± 0.5
*mann-Whitney u test; GrB – Granzyme B.
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The ratio between different subpopulations of T lympho-
cytes was determined, eg, CD4+:CD8+ and GrB+:CD8+ 
cells. In the entire cohort of patients, the proportion of CD4+ 
cells was 2.69 times higher than that of CD8+ cells, and the 
proportion of CD8+ cells was 3.82 times higher than that 
of GrB+ cells. The proportion of CD4+:CD8 and GrB+:CD8 
T cells was significantly higher in the group without recur-
rence than in the group with recurrence (P = 0.0002 [95% 
confidence interval -2.267 to -0.775], P = 0.039 [95% confi-
dence interval -1.428 to -0.0037], respectively) (Table 4).
disCussioN
The present study found differences in the number of TILs 
between the group of patients with recurrence and the 
group of patients without recurrence at the time of initial 
TUR. Moreover, it found significantly higher levels of CD3+ 
and CD8+ TILs in the group of patients with recurrence, 
while this was not confirmed for CD4+ and GrB+ cells. 
Since no patient had received any other form of treatment, 
we assume that these results reflect the real immune status 
of patients at the time of the initial operation, which is di-
rectly dependent on the immunobiology and pathophysi-
ology of the neoplastic disease.
Our findings on CD3+ TILs are similar to the results of Lip-
ponen et al (22), who found that CD3+ T cells in NMIBC 
predicted the progression of tumors and the related short 
recurrence-free survival. They hypothesized that unfavor-
able prognosis related to the presence of TILs may be con-
nected to the inhibitory mediators released by the tumor 
cells. These results are in contrast to the findings obtained 
by other authors, who reported good prognosis for the pa-
tients with higher number of TILs (23-25).
There are several possible explanations for the different 
literature findings regarding prognostic significance of 
TILs. One may be heterogeneity of the analyzed bladder 
cancers, since no distinction was made between the non-
muscle and muscle invasive type. This is why the present 
study was conducted on a homogenous group of patients, 
ie, only those who exhibited a solitary NMIBC. Other ex-
planations may be the use of different methodologies for 
TIL quantification and the lack of a different T cell subtypes 
analysis. According to our results, it was more appropri-
ate to determine the percentage of particular lymphocyte 
subsets than their absolute numbers.
The percentage of CD4+ cells in our study was higher 
than that of CD8+, the CD4+:CD8+ ratio being 3:1, 
irrespective of the recurrence of the disease. The percent-
age of CD4+ TILs was practically the same for non-recur-
rent and recurrent disease. This finding suggests that the 
infiltration of CD4+ TIL cells to the tumor site occurs under 
similar conditions.
Tumor infiltrating CD4+ cells play a central role in immune 
protection through their production of cytokines and 
chemokines, thus orchestrating immune responses. How-
ever, the CD4+:CD8+ TIL ratio was significantly lower in the 
group with the recurrence, or more specifically, this group 
had a greater number of CD8+ TILs, thus indicating that 
CD8+ TILs could be associated with bladder cancer recur-
rence.
To the best of our knowledge, this report is the first to 
describe the CD4+:CD8+ ratio in bladder cancer. This ra-
tio has already been confirmed as an immunobiological 
marker used for evaluation of the immune system status in 
patients with ovarian, colorectal, breast, and hepatocellular 
cancer (19,20,26,27).
In contrast to our study, Sharma et al (28) did not associ-
ate CD8+ TILs with disease-free survival and overall survival 
among patients with superficial non/muscle invasive blad-
der cancer, although CD8+ TILs did predict the survival in 
muscle invasive urothelial carcinoma. On the other hand, 
Jacobs et al (29) found a significant increase in the number 
of peripheral blood CD8+ lymphocytes in patients with re-
current NMIBC. They hypothesized that these peripheral 
immune suppressive cells facilitated tumor recurrences or 
that tumor recurrences caused an increase in the periph-
eral immunosuppressive lymphocytes (29).
We also analyzed data on anti-tumor effector cells such 
as GRB+. As expected, the number of GrB+ cells was low-
er than that of CD8+ TILs in the entire patient group, al-
though the GrB+:CD8+ ratio was significantly higher in the 
group with non-recurrence. This is consistent with the con-
cept of apoptotic role of GrB cells. GrB is a serine proteinase 
contained in cytoplasmic granules of activated cytotoxic T 
lymphocytes and natural killer cells. In the effector-target 
cell interaction, it is exocytosed and delivered inside the 
cytosol of target cells, where it induces apoptosis via pro-
teolysis of intracellular substrates (30). Since the levels of 
GrB+ TILs were similar in both patients with and without 
recurrence, the cytotoxic mechanism was probably not im-
paired. The cause of tumor recurrence may most likely be 
associated with immunosupression. It is well known that 
bladder cancer is an immunogenic malignancy, character-
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ized by the presence of TILs, which are probably capable 
of detecting neoplastic transformation and eradicating tu-
mors cells. On the other hand, tumor cells escape immune 
destruction, since immune system cells are known to play 
both protective and tumor-promoting roles during neo-
plastic transformation. Tumors undergo a process known 
as immunoediting, in which the tumor establishes a favor-
able microenviroment that enables it to avoid immune de-
struction (31). Patients with bladder cancer also exhibit a 
tumor-associated immunologic suppression, particularly 
evident as an impaired T-cell response. Indeed, bladder 
tumors have been shown to be infiltrated by T regulato-
ry cells and to express high levels of inhibitory cytokines, 
which may in part explain the immune dysfunction (32,33). 
A mechanism that has also been described for tumor-asso-
ciated immune suppression in certain cancers is the aber-
rant expression of inhibitory T-cell coregulatory molecules 
by tumor cells. Boorjian et al (34) investigated the aberrant 
expression of B7-H1, B7-H3, and PD-1 T-cell coregulatory 
molecules in urothelial cell carcinoma, showing that that 
H1 molecules predict mortality after cystectomy and may 
represent novel diagnostic and prognostic markers.
A balance of anti-tumor effector cells and tumor-promot-
ing suppressive and regulatory T-cells in a tumor influenc-
es not only the prognosis, but also the therapeutic impact 
of chemotherapy and immunotherapy (35). In NMIBC, this 
balance, although with different clinical outcomes, could 
be highlighted by CD4+:CD8+ and GrB+:CD8+ TIL ratios, 
which were higher in the group without recurrence. De-
spite the retrospective, non-randomized design of our 
study with possible statistical bias, we believe that these 
ratios could be used as a new and simple clinical immuno-
logical index for predicting recurrence, having therapeutic 
implications for the treatment of NMIBC patients.
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